ClinicalTrials.gg
RecruitingNCT04268121NEONECUpdated Jul 23, 2025

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

A Phase 2 interventional study of Neoadjuvant treatment and Adjuvant treatment in Neuroendocrine Carcinoma and Digestive Cancer, sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group. Recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Carcinoma, Neuroendocrine with a site in France — 7 open to participants now, 8 under way, 1 of them phase 3. Carcinoma, Neuroendocrine · France.

Planned enrollment
14th of 16
78 · median 157
Started
2021
with 1 other
Phase 2
10 of 17
4 open now
Registered
8th of 17
by date
Lead sponsor
1 of 17
GERCOR - Multidisciplinary Oncology Cooperative Group

Among the 17 studies in Carcinoma, Neuroendocrine with a site in France, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 in phase 2, and was the 8th registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

7 of the 17 studies in Carcinoma, Neuroendocrine with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Neuroendocrine with a site in France, or all of them as a file.
02

Study summary

NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC. The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to avoid the morbidity of conventional surgery.

The objective of the study is to improve relapse-free survival (RFS) in NEC patients treated with neoadjuvant chemotherapy followed by surgery or chemoradiotherapy.

In parallel, we will perform a prospective cohort study with patients whose diagnosis is made during surgery, who have not received neoadjuvant treatment, and who are offered an adjuvant treatment of the same type (combination of platinum and platinum salts and etoposide).

Read the detailed description

A total of 48 patients is to be included in phase II and 30 patients in prospective cohort during the inclusion period of phase II.

Phase II study treatment:

Neoadjuvant chemotherapy: Administration of 4 cycles of chemotherapy (3 months) with platinum based chemotherapy (carboplatin or cisplatin, at the choice of the investigator) + etoposide.

Surgery or chemoradiotherapy depending on the tumor localization (the irradiation modalities and associated chemotherapy treatment will be left to the discretion of the referring radiotherapists according to current recommendations for each localization).

Prospective cohort:

  • Surgery (prior to study entry)
  • Adjuvant chemotherapy : Administration of 4 cycles of chemotherapy (3 months) with platinum based chemotherapy (carboplatin or cisplatin, at the choice of the investigator) + etoposide.
03

Conditions studied

  • Neuroendocrine Carcinoma
  • Digestive Cancer

Keywords

  • Neoadjuvant treatment
  • Adjuvant treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase II

  1. proven digestive CNE, (the WHO 2017 classification: poorly differentiated and Ki 67 > 20%),
  2. Patients with localized CNE, without (computed tomography [CT], thoraco-abdominopelvic CT scan [TAP] according to 1.1; examinations performed no later than 21 days before starting the study treatment, possible locoregional lymph node involvement defined according to the TNM classification),
  3. Positron emission tomography (PET) and CT for lymph node status and elimination of secondary visceral and/or bone disorders, 4. Resectable tumor, according to the consensus decision made during local multidisciplinary surgical consultation meeting,

5. Age ≥ 18 years, 6. Written obtained from the patient, willing and able to comply with the protocol, 7. Registration in a National Health Care System (Protection Universelle Maladie [PUMa] included), 8. For female patients of , negative pregnancy test within 7 days before starting the study treatment.

Men and women are required to use a reliable and adequate during the study (if applicable) during the period of treatment and during 6 months from the last treatment administration.

Prospective cohort

  1. Patients with localized digestive CNE histologically proven on the operative specimen (the WHO 2017 classification: poorly differentiated and Ki 67> 20%),
  2. Localized, without metastasis on computed tomography [CT], thoracoabdominopelvic CT scan [TAP] RECIST 1.1, and/or locoregional lymph node involvement,
  3. Age ≥ 18 years,
  4. Written informed consent obtained from the patient, willing and able to comply with the protocol,
  5. Registration in a National Health Care System (PUMa - Protection Universelle Maladie included),
  6. For female patients of childbearing potential, negative pregnancy test within 7 days before starting the study treatment.

Men and women are required to use a reliable and adequate birth control methods during the study (if applicable) during the period of treatment and during 6 months from the last treatment administration.

Exclusion criteria

Exclusion Criteria:

Phase II

  1. Well-differentiated NEC, whatever the grade,
  2. disease,
  3. Cancer of unknown primary
  4. Organ failure that does not allow chemotherapy treatment,
  5. Previous within 5 years prior to the study except for cutaneous basal cell carcinoma and uterine cancer in situ
  6. Tumor with a mixed component (component accounts for ≥ 30%),
  7. Patient impossible to follow-up,
  8. Other than platinum-etoposide chemotherapy administrated,
  9. Tutelage or guardianship or patient protected by law

Prospective cohort

  1. Well-differentiated NEC, whatever the grade,
  2. Metastatic disease,
  3. Cancer of unknown primary
  4. Organ failure that does not allow chemotherapy treatment,
  5. Previous malignancy within 5 years prior to the study except for cutaneous basal cell carcinoma and uterine cancer in situ
  6. Tumor with a mixed component (component accounts for ≥ 30%),
  7. Patient impossible to follow-up,
  8. Other than platinum-etoposide chemotherapy administrated,
  9. Tutelage or guardianship or patient protected by law.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Phase II

    Prospective, open, multi center, one-arm, national phase II study evaluating the benefits in terms of disease-free survival (DFS) at 12 months after the administration of neoadjuvant treatment in patients with localized digestive neuroendocrine carcinomas

    Drug: Neoadjuvant treatment

  • Active comparator
    Prospective cohort

    Evaluation of DFS at 12 months in patients who underwent surgery and received adjuvant chemotherapy

    Drug: Adjuvant treatment

Interventions

  • DrugNeoadjuvant treatment

    4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy

    Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin

  • DrugAdjuvant treatment

    Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide

    Also known as: cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin

06

What researchers measure

Primary outcomes

  1. Relapse-free survival (RFS) - phase II

    Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.

    Time frame: At 12 months

  2. Relapse-free survival (RFS) - prospective cohort

    Interval between the date of the start of treatment (chemotherapy) and the date of first relapse or death (all causes). Relapse is defined according to RECIST version 1.1 criteria.

    Time frame: At 12 months

Secondary outcomes

  1. Number of patient in response in pre-operative or prior radiochemotherapy (if applicable) - Phase II

    according to RECIST 1.1

    Time frame: At 3 months after the beginning of treatment (up to 36 months)

  2. Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II

    Number of patients who do not benefit from surgery or radiochemotherapy (if applicable) - Phase II

    Time frame: Up to 39 months

  3. Number of patients operated after neoadjuvant chemotherapy or receiving radiochemotherapy (if applicable) - Phase II

    Number of patients operated after neoadjuvant chemotherapy or receiving

    Time frame: Up to 39 months

  4. Overall survival (OS) - Phase II

    Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.

    Time frame: up to 48 months

  5. Overall survival (OS) - Prospective cohort

    Overall survival (OS) is defined as the time from study enrollment to death (from any cause) or to the last date the patients was known to be alive.

    Time frame: Up to 48 months

  6. Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Phase II

    Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs. Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0

    Time frame: Up to 43 months

  7. Number of participants with treatment-related adverse events grade 3-4 as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0 - Prospective cohort

    Patients will be assessed for AEs throughout the study at every visit during treatment. Investigators using the NCI-CTCAE version 5.0 will grade the severity of AEs. Institute Common Terminology Criteria for Adverse Toxicity Study (NCI-CTCAE) version 5.0

    Time frame: Up to 43 months

07

Study locations

9 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jan 2027, 72 months after the start.

Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 91. This study's planned 72 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2020
First posted
Feb 13, 2020
StartActual
Jan 5, 2021
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2031
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04268121
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators
Fondation ARCAD
Responsible party
Sponsor
First posted
Feb 13, 2020
Start date
Jan 5, 2021
Primary completion
Jan 2027 (estimated)
Completion
Jan 2031 (estimated)
Last update
Jul 23, 2025

Study contacts

Anna PELLAT, MD
Contact
anna.pellat@aphp.fr
+33 (0) 1 49 28 23 45
Marie-Line GARCIA-LARNICOL
Contact
marie-line.garcia-larnicol@gercor.com.fr
Anna PELLAT
principal investigator · Saint-Antoine Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion